In 40 T2DM patients with coronary artery disease, the effect of a 6 month treatment with dapagliflozin on EAT volume and metabolic parameters (including HbA1c, tumor necrotic factor-α (TNF-α), and plasminogen activator inhibitor-1 (PAI-1) levels) was investigated. Here, SERPINE1 is linked to coronary artery disorder.